Metastatic colorectal cancer with microsatellite instability-high or mismatch repair-deficient status represents a distinct ...

Pfizer Inc. today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...

The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III ...

Natera, Inc. , a global leader in cell-free DNA and genetic testing, announced new data from the randomized, Phase III CALGB (Alliance) / SWOG 80702 study. The study will be presented today, Jan. 25, ...

Aspirin reduced disease recurrence in patients PI3K-mutated colorectal cancer, underscoring the value of early genomic ...

Aspirin use in patients with PI3K-mutated colorectal cancer helped to reduce disease recurrence, highlighting the importance ...